{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:16:45Z","timestamp":1790770605932,"version":"4.1.0"},"reference-count":53,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,18]]},"abstract":"Abstract<\/jats:title>\n \n Context<\/jats:title>\n Teprotumumab therapy for thyroid eye disease (TED) patients represents a major step forward. It targets and inhibits the insulin-like growth factor-1 receptor (IGF-1R), and its effectiveness is based on its interconnectedness with the thyrotropin receptor. However, IGF-1R has a ubiquitous expression and several adverse effects have been reported with teprotumumab use.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n Describing these adverse effects for better understanding is the purpose of this review.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We reviewed the oncological studies in which teprotumumab was initially used. Subsequently we reviewed the clinical trials for TED and then the case series and case reports associated with teprotumumab use since it is US Food and Drug Administration approval (January 2020). We focused on common and\/or serious adverse effects reported with the use of teprotumumab.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We described the common occurrence of hyperglycemia (10%-30% incidence), its risk factors and suggested management. Hearing changes are described, a broad spectrum from mild ear pressure to hearing loss (sensorineural mechanism). Risk factors, suggested monitoring, and possible upcoming therapies are reviewed. We also reviewed data on fatigue, muscle spasms, hair loss, weight loss, gastrointestinal disturbances, menstrual changes, and infusion reactions. We noted some discrepancies between adverse effects in oncological studies vs studies focused on TED, and we aimed to explain these differences.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The use of teprotumumab should consider patient's values and preferences in balancing the expected benefit with these potential risks. Future drugs targeting IGF-1R should investigate these adverse effects for a possible class effect. Combination therapies with different agents hopefully will be identified that maximize benefits and minimize risks.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/clinem\/dgad213","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T13:23:13Z","timestamp":1681824193000},"page":"e654-e662","source":"Crossref","is-referenced-by-count":54,"title":["The Adverse Effects Profile of Teprotumumab"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-8125","authenticated-orcid":false,"given":"Marius N","family":"Stan","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Mayo Clinic Rochester , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C","family":"Krieger","sequence":"additional","affiliation":[{"name":"Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"issue":"5","key":"2023112922383829200_dgad213-B1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41574-020-0340-1","article-title":"Shining a light on thyroid eye disease","volume":"16","author":"Ludgate","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2023112922383829200_dgad213-B2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"issue":"34","key":"2023112922383829200_dgad213-B3","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2011.36.6799","article-title":"Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer","volume":"29","author":"Ramalingam","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2023112922383829200_dgad213-B4","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-09-3220","article-title":"A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors","volume":"16","author":"Kurzrock","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023112922383829200_dgad213-B5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-013-2372-x","article-title":"Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies","volume":"73","author":"Mahadevan","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"34","key":"2023112922383829200_dgad213-B6","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023112922383829200_dgad213-B7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"key":"2023112922383829200_dgad213-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107502","article-title":"TSH\/IGF1 receptor crosstalk: mechanism and clinical implications","volume":"209","author":"Krieger","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"4","key":"2023112922383829200_dgad213-B9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"2023112922383829200_dgad213-B10","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2023112922383829200_dgad213-B11","doi-asserted-by":"crossref","first-page":"T45","DOI":"10.1530\/JME-17-0250","article-title":"IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy","volume":"61","author":"Mancarella","year":"2018","journal-title":"J Mol Endocrinol"},{"issue":"6","key":"2023112922383829200_dgad213-B12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bcp.12228","article-title":"The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy","volume":"77","author":"Ma","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2023112922383829200_dgad213-B13","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0519","article-title":"Hyperglycemia associated with targeted oncologic treatment: mechanisms and management","volume":"21","author":"Goldman","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"2023112922383829200_dgad213-B14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12032-013-0805-3","article-title":"Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer","volume":"31","author":"Singh","year":"2014","journal-title":"Med Oncol"},{"issue":"8","key":"2023112922383829200_dgad213-B15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.str.2022.05.007","article-title":"How insulin-like growth factor I binds to a hybrid insulin receptor type 1 insulin-like growth factor receptor","volume":"30","author":"Xu","year":"2022","journal-title":"Structure"},{"issue":"4","key":"2023112922383829200_dgad213-B16","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and Re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"4","key":"2023112922383829200_dgad213-B17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/clinem\/dgac627","article-title":"Teprotumumab-related hyperglycemia","volume":"108","author":"Amarikwa","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023112922383829200_dgad213-B18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.aace.2022.01.004","article-title":"A novel case of hyperglycemic hyperosmolar state after the use of teprotumumab in a patient with thyroid eye disease","volume":"8","author":"Shah","year":"2022","journal-title":"AACE Clin Case Rep"},{"issue":"8","key":"2023112922383829200_dgad213-B19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1210\/clinem\/dgac278","article-title":"Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline","volume":"107","author":"Korytkowski","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023112922383829200_dgad213-B20","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1210\/clinem\/dgac277","article-title":"A systematic review supporting the Endocrine Society clinical practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures","volume":"107","author":"Seisa","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023112922383829200_dgad213-B21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/IOP.0000000000001984","article-title":"Teprotumumab and hyperglycemia guidelines to monitor for hyperglycemia in teprotumumab","volume":"37","author":"Lee","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2023112922383829200_dgad213-B22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2014.00208","article-title":"Application of insulin-like growth factor-1 in the treatment of inner ear disorders","volume":"5","author":"Yamamoto","year":"2014","journal-title":"Front Pharmacol"},{"issue":"4","key":"2023112922383829200_dgad213-B23","first-page":"460","article-title":"IGF-I deficiency and hearing loss: molecular clues and clinical implications","volume":"10","author":"Varela-Nieto","year":"2013","journal-title":"Pediatr Endocrinol Rev"},{"issue":"2","key":"2023112922383829200_dgad213-B24","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/IOP.0000000000002078","article-title":"Rifle blast exacerbating hearing loss in a patient treated with teprotumumab for thyroid eye disease","volume":"38","author":"Reed","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"2023112922383829200_dgad213-B25","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-248335","article-title":"Teprotumumab-associated chronic hearing loss screening and proposed treatments","volume":"15","author":"Chow","year":"2022","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2023112922383829200_dgad213-B26","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1097\/MAO.0000000000003428","article-title":"Sensorineural hearing loss after teprotumumab therapy for thyroid eye disease: a case report","volume":"43","author":"Ding","year":"2022","journal-title":"Otol Neurotol"},{"issue":"8","key":"2023112922383829200_dgad213-B27","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/00034894211042740","article-title":"Ototoxicity and teprotumumab","volume":"131","author":"Highland","year":"2022","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2023112922383829200_dgad213-B28","article-title":"Audiology findings in patients with teprotumumab associated otologic symptoms","volume":"24","author":"Yu","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"2023112922383829200_dgad213-B29","doi-asserted-by":"crossref","DOI":"10.1177\/2473974X221097097","article-title":"Audiologic demonstration of ototoxicity from teprotumumab treatment in a patient with thyroid eye disease","volume":"6","author":"Najjar","year":"2022","journal-title":"OTO Open"},{"issue":"1","key":"2023112922383829200_dgad213-B30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/IOP.0000000000001995","article-title":"Teprotumumab and hearing loss: case series and proposal for audiologic monitoring","volume":"38","author":"Belinsky","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2023112922383829200_dgad213-B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2023112922383829200_dgad213-B32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archotol.1993.01880180081015","article-title":"High-frequency monitoring for early detection of cisplatin ototoxicity","volume":"119","author":"Fausti","year":"1993","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"2","key":"2023112922383829200_dgad213-B33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ije\/dyw243","article-title":"Diabetes mellitus and the incidence of hearing loss: a cohort study","volume":"46","author":"Kim","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"3","key":"2023112922383829200_dgad213-B34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5152\/iao.2021.8549","article-title":"Effects of insulin-like growth factor (IGF-1) in patients with sensorineural hearing loss","volume":"17","author":"Dave","year":"2021","journal-title":"J Int Adv Otol"},{"issue":"9","key":"2023112922383829200_dgad213-B35","doi-asserted-by":"crossref","first-page":"e1376","DOI":"10.1097\/MAO.0000000000003263","article-title":"Intratympanic insulin-like growth factor-1 administration via the otic bulla in a severe facial paralysis model","volume":"42","author":"Kimura","year":"2021","journal-title":"Otol Neurotol"},{"issue":"1","key":"2023112922383829200_dgad213-B36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbi.2005.02.003","article-title":"Effects of insulin-like growth factor-I on cytokine-induced sickness behavior in mice","volume":"20","author":"Bluth\u00e9","year":"2006","journal-title":"Brain Behav Immun"},{"issue":"4","key":"2023112922383829200_dgad213-B37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41575-018-0091-9","article-title":"Fatigue in IBD: epidemiology, pathophysiology and management","volume":"16","author":"Borren","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2023112922383829200_dgad213-B38","article-title":"Early experience with teprotumumab for chronic thyroid eye disease","volume":"19","author":"Ozzello","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"2023112922383829200_dgad213-B39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yfrne.2012.06.002","article-title":"Neurodevelopmental effects of insulin-like growth factor signaling","volume":"33","author":"O\u2019Kusky","year":"2012","journal-title":"Front Neuroendocrinol"},{"issue":"1","key":"2023112922383829200_dgad213-B40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ana.26383","article-title":"A role for insulin-like growth factor 1 in the generation of epileptic spasms in a murine model","volume":"92","author":"Ballester-Rosado","year":"2022","journal-title":"Ann Neurol"},{"issue":"6","key":"2023112922383829200_dgad213-B41","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2023112922383829200_dgad213-B42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000479333","article-title":"Further clinical evidence for the effect of IGF-1 on hair growth and alopecia","volume":"4","author":"Tr\u00fceb","year":"2018","journal-title":"Skin Appendage Disord"},{"issue":"5","key":"2023112922383829200_dgad213-B43","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.0022-202X.2005.23946.x","article-title":"IGF-I signalling controls the hair growth cycle and the differentiation of hair shafts","volume":"125","author":"Weger","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2023112922383829200_dgad213-B44","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000077839","article-title":"Laron syndrome (primary growth hormone insensitivity): a unique model to explore the effect of insulin-like growth factor 1 deficiency on human hair","volume":"208","author":"Lurie","year":"2004","journal-title":"Dermatology"},{"issue":"4","key":"2023112922383829200_dgad213-B45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/thy.2021.0176","article-title":"Mechanisms in Graves eye disease: apoptosis as the end point of insulin-like growth factor 1 receptor inhibition","volume":"32","author":"Morshed","year":"2022","journal-title":"Thyroid"},{"issue":"9","key":"2023112922383829200_dgad213-B46","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ajpath.2015.05.020","article-title":"Insulin-like growth factor-1 contributes to mucosal repair by beta-arrestin2-mediated extracellular signal-related kinase signaling in experimental colitis","volume":"185","author":"Chen","year":"2015","journal-title":"Am J Pathol"},{"key":"2023112922383829200_dgad213-B47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112239","article-title":"Relationship between IGF-1 and body weight in inflammatory bowel diseases: cellular and molecular mechanisms involved","volume":"144","author":"Guijarro","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2023112922383829200_dgad213-B48","article-title":"A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease","volume":"22","author":"Safo","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"2023112922383829200_dgad213-B49","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/IOP.0000000000001943","article-title":"New-onset of inflammatory bowel disease in a patient treated with teprotumumab for thyroid associated ophthalmopathy","volume":"37","author":"Ashraf","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2023112922383829200_dgad213-B50","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2147\/TCRM.S303057","article-title":"Efficacy and safety of teprotumumab in thyroid eye disease","volume":"17","author":"Teo","year":"2021","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"2023112922383829200_dgad213-B51","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242153","article-title":"Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease","volume":"14","author":"Hoang","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"10","key":"2023112922383829200_dgad213-B52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11910-017-0785-3","article-title":"Neurological complications of therapeutic monoclonal antibodies: trends from oncology to rheumatology","volume":"17","author":"Gill","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2023112922383829200_dgad213-B53","first-page":"3","author":"Horizon Therapeutics USA Inc LF, IL","year":"2022"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad213\/50209195\/dgad213.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/9\/e654\/53940327\/dgad213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/9\/e654\/53940327\/dgad213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T17:43:25Z","timestamp":1701279805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/9\/e654\/7127890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,18]]},"published-print":{"date-parts":[[2023,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad213","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,4,18]]}}}